Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin
Table 2
Biomarkers at baseline, prior to cycle 3 and at 2 months’ follow up, for all patients and by treatment arm.